Lipidation of Polyethylenimine-based Polyplex Increases Serum Stability of Bioengineered RNAi Agents and Offers More Consistent Tumoral Gene Knockdown in Vivo

Overview

Journal Int J Pharm

Specialties Chemistry
Pharmacology

Date 2018 Jun 13

PMID 29894758

Citations 21

Authors

Qian-Yu Zhang

Pui Yan Ho

Mei-Juan Tu

Joseph L Jilek

Qiu-Xia Chen

Su Zeng

Ai-Ming Yu

Affiliations

Soon will be listed here.

Abstract

Recently we have established a novel approach to produce bioengineered noncoding RNA agents (BERAs) in living cells that carry target RNAi molecules (e.g., siRNA and miRNA) and thus act as "prodrugs". Using GFP-siRNA-loaded BERA (BERA/GFP-siRNA) as a model molecule, this study was to define the in vitro and in vivo knockdown efficiency of BERAs delivered by liposome-polyethylenimine nanocomplex (lipopolyplex or LPP). Compared to in vivo-jetPEI® (IVJ-PEI) and polyplex formulations, LPP offered greater protection of BERA/GFP-siRNA against degradation by serum RNases. Particle sizes and zeta potentials of LPP nanocomplex remained stable over 28 days when stored at 4 °C. Furthermore, comparable levels of BERA/GFP-siRNA were delivered by LPP and IVJ-PEI to luciferase/GFP-expressing human SK-Hep1-Luc-GFP or A549-Luc-GFP cells, which were selectively processed into target GFP-siRNA and subsequently knocked down GFP mRNA and protein levels. In addition, LPP-carried BERA/GFP-siRNA was successfully delivered into xenograft tumors and offered more consistent knockdown of tumoral GFP mRNA level in an orthotopic hepatocellular carcinoma (HCC) SK-Hep1-Luc-GFP xenograft mouse model, while IVJ-PEI formulation showed larger variation. These findings demonstrated that lipidation of polyplexes improved serum stability of biologic RNAi molecules, which was efficiently delivered to orthotopic HCC tissues to knock down target gene expression.

Citing Articles

Molecular Engineering of Functional SiRNA Agents.

Batra N, Tu M, Yu A ACS Synth Biol. 2024; 13(6):1906-1915.

PMID: 38733599 PMC: 11197084. DOI: 10.1021/acssynbio.4c00181.

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer.

Chen Y, Tu M, Han F, Liu Z, Batra N, Lara P Acta Pharm Sin B. 2023; 13(10):4273-4290.

PMID: 37799388 PMC: 10547963. DOI: 10.1016/j.apsb.2023.07.011.

Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas.

Gupta R, Salave S, Rana D, Karunakaran B, Butreddy A, Benival D Pharmaceutics. 2023; 15(5).

PMID: 37242677 PMC: 10222274. DOI: 10.3390/pharmaceutics15051435.

Global trends in research on miRNA-microbiome interaction from 2011 to 2021: A bibliometric analysis.

Yan X, Yao J, Li Y, Zhang W, Xi M, Chen M Front Pharmacol. 2022; 13:974741.

PMID: 36110534 PMC: 9468484. DOI: 10.3389/fphar.2022.974741.

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.

Ning S, Liu C, Lou W, Yang J, Lombard A, DAbronzo L Mol Cancer Ther. 2022; 21(10):1594-1607.

PMID: 35930737 PMC: 9547958. DOI: 10.1158/1535-7163.MCT-22-0216.

References

Kim J, Choi S, Kim C, Park J, Ahn W, Kim C . Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J Pharm Pharmacol. 2003; 55(4):453-60. DOI: 10.1211/002235702928. View

Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N . Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release. 2004; 100(1):41-52. DOI: 10.1016/j.jconrel.2004.07.033. View

Lv H, Zhang S, Wang B, Cui S, Yan J . Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006; 114(1):100-9. DOI: 10.1016/j.jconrel.2006.04.014. View

Ponchon L, Dardel F . Recombinant RNA technology: the tRNA scaffold. Nat Methods. 2007; 4(7):571-6. DOI: 10.1038/nmeth1058. View

Dunham C, Conn G . Recombinant RNA expression. Nat Methods. 2007; 4(7):547-8. DOI: 10.1038/nmeth0707-547. View

Gao K, Huang L . Nonviral methods for siRNA delivery. Mol Pharm. 2009; 6(3):651-8. PMC: 2692493. DOI: 10.1021/mp800134q. View

Castanotto D, Rossi J . The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009; 457(7228):426-33. PMC: 2702667. DOI: 10.1038/nature07758. View

Whitehead K, Langer R, Anderson D . Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129-38. PMC: 7097568. DOI: 10.1038/nrd2742. View

Howard K . Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev. 2009; 61(9):710-20. DOI: 10.1016/j.addr.2009.04.001. View

10.

Puri A, Loomis K, Smith B, Lee J, Yavlovich A, Heldman E . Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2010; 26(6):523-80. PMC: 2885142. DOI: 10.1615/critrevtherdrugcarriersyst.v26.i6.10. View

11.

Schafer J, Hobel S, Bakowsky U, Aigner A . Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010; 31(26):6892-900. DOI: 10.1016/j.biomaterials.2010.05.043. View

12.

Perche F, Benvegnu T, Berchel M, Lebegue L, Pichon C, Jaffres P . Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine. 2011; 7(4):445-53. DOI: 10.1016/j.nano.2010.12.010. View

13.

Burnett J, Rossi J, Tiemann K . Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011; 6(9):1130-46. PMC: 3388104. DOI: 10.1002/biot.201100054. View

14.

Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O . Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2011; 50(1):76-8. DOI: 10.5414/cpp50076. View

15.

Jayaraman M, Ansell S, Mui B, Tam Y, Chen J, Du X . Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012; 51(34):8529-33. PMC: 3470698. DOI: 10.1002/anie.201203263. View

16.

Kusumoto K, Akita H, Ishitsuka T, Matsumoto Y, Nomoto T, Furukawa R . Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS Nano. 2013; 7(9):7534-41. DOI: 10.1021/nn401317t. View

17.

Yang J, Hendricks W, Liu G, McCaffery J, Kinzler K, Huso D . A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc Natl Acad Sci U S A. 2013; 110(36):14717-22. PMC: 3767543. DOI: 10.1073/pnas.1313330110. View

18.

Ewe A, Schaper A, Barnert S, Schubert R, Temme A, Bakowsky U . Storage stability of optimal liposome-polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery. Acta Biomater. 2014; 10(6):2663-73. DOI: 10.1016/j.actbio.2014.02.037. View

19.

Li M, Wang W, Wu W, Huang M, Yu A . Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos. 2014; 42(11):1791-5. PMC: 4201134. DOI: 10.1124/dmd.114.060145. View

20.

Zhang Q, Ran R, Zhang L, Liu Y, Mei L, Zhang Z . Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system. J Control Release. 2014; 197:208-18. DOI: 10.1016/j.jconrel.2014.11.010. View